Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CECR2 | Q9BXF3 | 6/20 | 0.60 |
| ▸ | TAF1 | P21675 | 5/20 | 0.60 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.60 |
| ▸ | BRD4 | O60885 | 10/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753983 | 0.90 | BRD9 (0.66) | CECR2TAF1BRD9BRD4HPGD | |
| SCHEMBL17753900 | 0.88 | BRD9 (0.60) | CECR2TAF1BRD9BRD4HPGD | |
| SCHEMBL17753895 | 0.86 | TAF1 (0.58) | CECR2TAF1BRD9BRD4HPGD | |
| SCHEMBL17753966 | 0.86 | BRD9 (0.64) | CECR2TAF1BRD9BRD4HPGD | |
| SCHEMBL17754066 | 0.85 | BRD9 (0.62) | CECR2TAF1BRD9BRD4HPGD | |
| SCHEMBL17753997 | 0.84 | TAF1 (0.64) | CECR2TAF1BRD9BRD4HPGD | |
| SCHEMBL17753952 | 0.81 | TAF1 (0.57) | CECR2TAF1BRD9BRD4KDM4E | |
| SCHEMBL17753996 | 0.80 | TAF1 (0.56) | CECR2TAF1BRD9BRD4HPGD | |
| SCHEMBL17753988 | 0.80 | TAF1 (0.58) | CECR2TAF1BRD9BRD4HPGD | |
| SCHEMBL17753965 | 0.79 | BRD9 (0.72) | CECR2TAF1BRD9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CECR2 184/4885TAF1 439/4885BRD9 16/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CECR2 184/4885TAF1 439/4885BRD9 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.